N/A N=30 Defining the Conjunctival Staining Method: Instillation Volume and Time Course to Assess Staining With Lissamine Green
Conjunctival Staining
Primary: Conjunctival Staining at 1 Minute — 3.29; 3.67; 3.98 Units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=26 Evaluation of Contact Lenses and Conjunctival Staining in Normal Patients
Conjunctival Staining
Primary: Mean Circumlimbal Conjunctival Staining Score — 6.39; 5.55; 5.68 Units on a scale
N/A N=60 Corneal Staining and Physiological Compromise After Eight Hours of Soft Contact Lens Wear
Contact Lens-induced Corneal Fluorescein Staining
Primary: The Primary Outcome Measure Will be Corneal Epithelial Dye Diffusion Rate in Nanometers Per Second, for the Test and Control Eyes. — 0.0567; 0.0583 nanometers per second
Phase 4 N=50 Corneal and Conjunctival Sensitivity and Staining Study
Myopia · Hyperopia
Primary: Corneal Sensitivity — 26.9; 25.5 percent CO2
N/A N=33 Clinical Biocompatibility Evaluation of Contact Lens Coatings
Refractive Errors · Ametropia
Primary: Average Percent Area of Solution-related Corneal Staining — 7.01; 12.82; 13.54; 7.58 percentage of area
Phase 4 N=13 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients
Allergic Conjunctivitis
Primary: Patient-Assessed Ocular Itching — 2.2; 2.2; 0.5; 0.5 units on a scale
Phase 4 N=8 Study of the Presence and Extent of Corneal Disturbance Associated With B+L Biotrue MPS Used With B+L PureVision Lenses
Keratitis
Primary: Number of Participants Wiith Corneal Staining — 1; 6 participants
Phase 4 N=162 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora
Bacterial Conjunctivitis
Primary: Susceptability Changes in Streptococcus Pneumoniae Distal to the Site of Instillation — 0; 0; 0; 0 Percent of resistant isolates
N/A N=44 Determination of Cell Population in Solution-Induced Corneal Staining (SICS) and Symptomatic Versus Asymptomatic Lens Wearers
Refractive Error · Dry Eye
Primary: Mean Number of Viable Epithelial Cells Collected Directly From the Ocular Surface After 2 Hours and 4 Hours of Wear, Phase 1 — 15; 20; 18; 22 cells
N/A N=24 Open Eye Corneal Swelling With Daily Disposable Contact Lenses and no Lens Wear
Corneal Swelling
Primary: Percentage Change From Baseline of Corneal Swelling 8 Hours Post Fit — 0.07; -0.02; 0.14; -0.06 percentage of change from baseline
Phase 2 N=269 Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis
Bacterial Conjunctivitis
Primary: Clinical Resolution of Baseline Bacterial Conjunctivitis (Day 8 or 9) — 37; 20 Participants
N/A N=94 Clinical Evaluation of Systane® ULTRA Compared to OPTIVE® in Ocular Surface Staining
Dry Eye Syndrome
Primary: Mean Change From Baseline in Total Ocular Surface Staining (TOSS) Score at Day 35 (Phase I) — -2.2; -1.7 units on a scale
Phase 1 N=5 Effect of Ranibizumab on Malignant Conjunctival Neoplasia
Conjunctival Neoplasms
Primary: Number of Patients Assessed for Safety and Tolerability — 5 participants
Phase 4 N=16 Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model
Chronic Allergic Conjunctivitis
Primary: Inflammation Change From Baseline to Day 6 — -1.2; -0.19 score on a scale
Phase 2 N=282 Mucin Balls and Corneal Inflammation Events
Corneal Inflammation · Corneal Infiltrative Events
Primary: Corneal Infiltrate Events - Phase I — 18.6; 5.7 percentage of subjects
N/A N=30 Impact of Soft Contact Lenses on Lid-Parallel Conjunctival Folds
Lid-Parallel Conjunctival Folds
Primary: Lid-Parallel Conjunctival Folds (LIPCOF) — 1.95; 1.75; 1.70; 1.40 Score
N/A N=21 Effect of Olopatadine on Allergic Tear Mediators
Allergic Conjunctivitis
Primary: Study Examined Whether the Incubation of Human Conjunctival Epithelial Cells With Tears Pooled From Allergic Subjects (One Eye With and Other Eye Without Olopatadine…
Phase 4 N=11 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
Allergic Conjunctivitis
Primary: Ocular Itching Change From Baseline to Day 11 — -1.1; -0.45 units on a scale
Phase 2 N=129 Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis
Acute Bacterial Conjunctivitis
Primary: Clinical Cure Rate — 37; 31; 27; 33 Participants — p=0.0137
N/A N=28 Reducing Adenoviral Patient Infected Days
Conjunctivitis · Adenoviral Conjunctivitis
Primary: Percent Change From Peak Viral Load — 1.9; 13.2 Percent of peak Viral Load — p=0.02
Phase 3 N=345 Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Mean Ocular Itching at Onset of Action — 0.38; 0.47; 0.59; 1.91 units on a scale
Phase 3 N=957 A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.
Acute Bacterial Conjunctivitis
Primary: Clinical Resolution of Baseline Bacterial Conjunctivitis — 90; 63 Participants
Phase 3 N=130 Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Ocular Itching — 0.4; 1.9; 0.4; 0.5 Units on a scale
N/A N=36 Three Daily Wear Monthly Replacement Silicone Hydrogel Contact Lenses With Two Multi-purpose Disinfecting Solution Combinations
Refractive Errors
Primary: Average Percent Area of Corneal Staining — 2.93; 0.45; 6.06; 3.52 percentage of area
Phase 2 N=164 Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Mean Change From Baseline in Ocular Redness, Area Under the Curve From Time Zero to Hour 10 [AUC (0-10)] at Day 7 — -2.8; -4.7; -8.1; -4.5 hours x units on a scale
N/A N=29 Short-Term Evaluation of Corneal Staining With Balafilcon A Lenses and Two Multi-Purpose Solutions
Corneal Staining
Primary: Corneal Staining by Wear Time — 19; 15; 19; 7 participants
Phase 4 N=23 Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Change From Baseline in Ocular Itching at 14 Days — 2.17; 1.82 units on a scale
Phase 4 N=24 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment
Bacterial Conjunctivitis
Primary: Exploratory Outcomes From Digital Photography — 17; 7 Participants
Phase 3 N=101 Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model
Allergic Conjunctivitis
Primary: Ocular Itching at Duration of Action (16 Hours Post-dose) — 1.91; 2.00; 1.65; 2.48 units on a scale
Phase 2 N=70 Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Ocular Itching — 0.508; 0.139; 2.485; 2.535 score on a scale — p=0.0882